Table 1

Details of the nine positive thrombectomy trials

Trial	Trial dates	Centres	Participants	Primary outcome measure	Age (years)	Onset of symptoms		NIHSS
Trial	Trial dates	Centres	Participants	Primary outcome measure	Age (years)	IV r-tPA	MT	NIHSS
MR CLEAN³⁵	2010–14	16	502	mRS at 90 days	≥18	≤4.5	≤6	>1
REVASCAT³⁶*	2012–14	4	206	mRS at 90 days	18–80‡	≤4.5	≤8	>5
EXTEND 1A³⁷†	2012–14	10	70	Reperfusion at 24 hours, NIHSS at day 3	≥18	≤4.5	≤6	No restriction
SWIFT-prime³⁸†	2012–14	39	196	mRS at 90 days	18–80	≤3.5	≤6	8–29
ESCAPE³⁹†	2013–14	22	316	mRS at 90 days	≥18	≤4.5	≤12	>5
THRACE⁴⁰†	2010–15	26	402	mRS≤2 at 90 days	18–80	≤4	≤5	10–25
THERAPY⁴¹*	2012–14	36	108	mRS≤2 at 90 days	18–85	≤4.5§	≤8¶	>7
PISTE⁴²	2013–15	10	65	mRS≤2 at 90 days	≥18	≤4.5	6	No restriction
EASI⁴³*	2013–14	1	77	mRS≤2 at 3 months	≥18	<3	≤6	>7**

*Enrolment was halted early after positive results for thrombectomy were reported from other similar trials.
†Trial stopped early due to efficacy.
‡After enrolling 160 patients, inclusion criteria were modified to include patients up to the age of 85 years with an ASPECTS >8.
§Three-hour limit if patient>80 with diabetes, previous stroke, previous anticoagulation and NIHSS>25.
¶Revised protocol reduced cut-off to 5 hours.
**Or the presence of clinical imaging mismatch, and suspected or proven occlusion of the M1 or M2 segments of the middle cerebral artery, supraclinoid internal carotid artery or basilar artery.
IV r-tPA, intravenous thrombolysis with recombinant tissue-type plasminogen activator; mRS, modified Rankin Scale; MT, mechanical thrombectomy; NIHSS, National Institutes of Health Stroke Scale.